Abstract 2783
Background
Individual Care plans should be a co-creation between the patient and the health care provider, and should be updated by the contact nurse (CN) that is the patients’ main point of contact. Until recently the individual care plans for patients with Head & Neck cancer (H&N) in our region constituted of extensive written information in a ring binder and in addition a treatment plan from the medical records were printed and given to the patient. This quality improvement project aims to implement a digital and interactive version of the care plan, with a greater possibility to tailor information and increased availability. The implementation process contained of both the introduction of the digital tool (the care plan) and also new work processes for the nurses.
Methods
We followed the Plan Do Study Act approach. A clinical nurse leader together with the designer of the and an IT-technician worked together with the preparations (education, testing and risk assessment). All patients with H&N cancer could choose a standard care plan or the new digital format. The digital care plan was prepared by the CN. A person-centered approach was adopted for the digital care plans, with mandatory questions at the first visit with the CN; “What is important to you? - What is important that I know about you?”.
Results
30 % of chose the digital version of the individual care plan (n = 45) (patients were asked to choose either printed or digital). Patients and nurses were asked to give feedback on the content, usefulness and to suggest improvements. The first evaluation from the patients suggests improved patient participation and satisfaction. The CN stated that the digital care plan had advantages such as less time consuming, improved communication with the patients and supporting person-centered care. The patients can interact with the CN and may also use different symptom assessment scales and were involved during the whole implementation phase.
Conclusions
There is a potential for increased use of screening tools and systematic assessment of symptoms with the digital version of the IWCP. The mandatory question gave important information to the CN to consider. A designated nurse leader involved in the process is important during the implementation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Regional Cancer Center Stockholm Gotland.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5760 - Landscape of PD-L1 expression status in Chinese solid tumor patients.
Presenter: Yi Zhong
Session: Poster Display session 3
Resources:
Abstract
3733 - Anti-cancer and immunomodulatory effects of cobimetinib in triple negative breast cancer
Presenter: Chun-Yu Liu
Session: Poster Display session 3
Resources:
Abstract
4426 - Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for therapeutics
Presenter: Jacob Adashek
Session: Poster Display session 3
Resources:
Abstract
2752 - Insights into the Tumor Immune Microenvironment using Tissue Phenomics to Drive Cancer Immunotherapy
Presenter: Martin Groher
Session: Poster Display session 3
Resources:
Abstract
5713 - Immune competent somatic mosaic model of colorectal cancer
Presenter: Stefania Napolitano
Session: Poster Display session 3
Resources:
Abstract
1898 - Genomic correlates of response to anti-PDL1 Atezolizumab in non-small-cell lung cancer OAK and POPLAR trials
Presenter: Hari Singhal
Session: Poster Display session 3
Resources:
Abstract
3246 - Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
3311 - High level of activity of Nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program
Presenter: Christophe Tournigand
Session: Poster Display session 3
Resources:
Abstract
2314 - TP53 and ATM Co-mutation Predicts Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Presenter: Yu Chen
Session: Poster Display session 3
Resources:
Abstract
4692 - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
Presenter: Raquel Laza-Briviesca
Session: Poster Display session 3
Resources:
Abstract